The Influence of Gut Microbiota on Guillain-Barré Syndrome: Investigating Microbial Metabolites, Biomarkers, and Novel Treatment Approaches

Category	Detail
Condition
Key Mechanisms	Immune-mediated demyelination or axonal injury of the peripheral nervous system, influenced by gut microbiota and its metabolites, including SCFAs.
Target Population
Care Setting

GBS is characterized by rapidly progressive limb weakness and can lead to respiratory failure.
Gut microbiota plays a significant role in modulating immune responses relevant to GBS, particularly through metabolites like SCFAs.
Specific microbial taxa and metabolites may serve as diagnostic or prognostic biomarkers.
Microbiota-targeted therapies, including probiotics and fecal microbiota transplantation, are emerging as potential treatments.
Dietary patterns influence gut microbiota composition and may affect GBS susceptibility.

Immunotherapy remains the cornerstone of GBS management.
Consider microbiota-targeted therapies as adjuncts, including probiotics and dietary modifications.

Probiotics and prebiotics may help restore beneficial microbiota and improve outcomes, supported by emerging clinical evidence.

Integrate dietary assessments to understand microbiota influences.
Monitor for signs of dysbiosis in GBS patients and adjust treatment accordingly.
Consider personalized microbiota-based interventions in treatment plans.

Clinical Scorecard: The Influence of Gut Microbiota on Guillain-Barré Syndrome: Investigating Microbial Metabolites, Biomarkers, and Novel Treatment Approaches